Noul, an artificial intelligence (AI) powered blood and cancer diagnostics firm, has inked a memorandum of understanding (MOU) with Infinite Medical, a U.S.-based specialist in stem cell regenerative therapies, the company announced on Monday.
Noul aims to broaden the applications of its AI blood analysis solution, miLab™ BCM, in the stem cell field.
The company will use miLab BCM to quantitatively track patient status changes in regenerative medicine, including stem cell transplants, and explore data-driven management possibilities.
Noul is expanding miLab’s scope beyond traditional hospital lab blood tests and analysis, venturing into monitoring blood changes during regenerative treatments.
The partnership will involve collecting and analyzing blood-based biomarker data on patient condition changes to evaluate potential applications across various medical settings. The firms also plan to develop case studies based on future validation results and share their findings publicly.
Noul’s Chief Executive Officer (CEO), Im Chan-yang, stated that this partnership will allow us to further refine miLab’s applications. It’ll use performance validation in the North American market as a launchpad to accelerate the entry into advanced global markets.